The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform
Martijn A Oudijk - One of the best experts on this subject based on the ideXlab platform.
-
effect of nifedipine and Atosiban on perinatal brain injury secondary analysis of the apostel iii trial
Ultrasound in Obstetrics & Gynecology, 2018Co-Authors: T A Nijman, Christiana A Naaktgeboren, Martijn Goedhart, T R De Haan, Daniel C Vijlbrief, Ben Willem J Mol, Mjnl Benders, Arie Franx, Martijn A OudijkAbstract:Objective Brain injury in prematurely born neonates is strongly associated with poor neurodevelopmental outcome. The aim of our study is to evaluate if nifedipine reduces overall brain injury compared to Atosiban in women with threatened preterm birth. Methods We performed a secondary analysis of the APOSTEL III-trial (Dutch Clinical Trial Registry, number NTR2947). This was a randomized clinical trial that allocated women with threatened preterm labor between 25–34 weeks of gestation to nifedipine or Atosiban. For this secondary analysis, we included women delivering at ≤ 32 weeks of gestational age in the two main contributing centers. The primary outcome was the presence of brain injury. Brain injury was defined as the existence of abnormalities on ultrasound investigation, it was divided into mild and severe brain injury. To evaluate type and severity of brain injury, all neonatal ultrasounds made during neonatal intensive care admission and medium care admission were analyzed. A sensitivity analysis assessing differences in baseline or known risk factors for brain injury, was performed to test the robustness of our results. Results We studied 117 neonates, born from 102 women, of which 51 neonates had been exposed to nifedipine and 66 to Atosiban. Brain injury was observed in 22 neonates (43.1%) in the nifedipine group and in 37 (56.1%) neonates in the Atosiban (OR 0.60; 95% CI: 0.29-1.24). Mild brain injury was comparable between nifedipine (33.3%) and Atosiban (48.5%, OR 0.53; 95% CI 0.25-1.13). Severe brain injury was also comparable between the groups, 9.8% for nifedipine and 7.6% for Atosiban (OR 1.33; 95% CI 0.36-4.85). Intraventricular hemorrhage (≥ grade I) was most frequently seen; 18 neonates (35.3%) in the nifedipine group versus 25 neonates (37.9%) in the Atosiban group (OR 0.90; 95% CI 0.42-1.91). The sensitivity analysis, with adjustment for maternal age and gestational age at randomization, showed no statistical difference of brain injury (OR 0.58; 95% CI 0.27-1.27). Conclusion In children born before 32 weeks after the use of tocolytics, the prevalence of brain injury was high. No significant differences were found between nifedipine and Atosiban in terms of overall brain injury. However, as this study was a secondary analysis of the APOSTEL III trial, it was underpowered for brain injury, as the latter was not the primary outcome of APOSTEL III.
Waldemar Kuczynski - One of the best experts on this subject based on the ideXlab platform.
-
effect of Atosiban on rabbit embryo development and human sperm motility
Fertility and Sterility, 2007Co-Authors: Piotr Pierzynski, Allan D Rasmussen, Bartek Gajda, Zdzislaw Smorag, Waldemar KuczynskiAbstract:Objective To investigate embryotoxic potential and effects on human sperm motility of the mixed vasopressin V 1a /oxytocin receptor antagonist Atosiban considered for novel indication of improvement of uterine receptivity in embryo-transfer recipients. Design One-cell rabbit embryo bioassay and human sperm motility bioassay were performed in control media or in media containing Atosiban. Setting Private center of reproductive medicine and academic research institute of reproduction biotechnology. Animal(s) Rabbit females (New Zealand and California, N=15) aged 4.5–6.5 months. Intervention(s) In vitro exposure of one-cell rabbit embryos and human sperm to Atosiban in the range of therapeutic concentrations clinically occurring in human beings. Main Outcome Measure(s) Embryo development and sperm motility. Result(s) Preimplantation development of one-cell rabbit embryos was not affected by Atosiban in the concentrations ≤15,000 nM, which was 50-fold higher than the mean plasma concentration reached during regular therapy (300 nM). Atosiban did not affect human sperm motility in concentrations of ≤3,000 nM, in other words, 10 times the human mean plasma concentration. Conclusion(s) Clinical application of Atosiban in the proposed indication may be safe for embryos because it is compatible with preimplantation rabbit embryo development and human sperm motility.
-
effect of Atosiban on rabbit embryo development and human sperm motility
Fertility and Sterility, 2007Co-Authors: Piotr Pierzynski, Allan D Rasmussen, Bartek Gajda, Zdzislaw Smorag, Waldemar KuczynskiAbstract:Objective To investigate embryotoxic potential and effects on human sperm motility of the mixed vasopressin V 1a /oxytocin receptor antagonist Atosiban considered for novel indication of improvement of uterine receptivity in embryo-transfer recipients. Design One-cell rabbit embryo bioassay and human sperm motility bioassay were performed in control media or in media containing Atosiban. Setting Private center of reproductive medicine and academic research institute of reproduction biotechnology. Animal(s) Rabbit females (New Zealand and California, N=15) aged 4.5–6.5 months. Intervention(s) In vitro exposure of one-cell rabbit embryos and human sperm to Atosiban in the range of therapeutic concentrations clinically occurring in human beings. Main Outcome Measure(s) Embryo development and sperm motility. Result(s) Preimplantation development of one-cell rabbit embryos was not affected by Atosiban in the concentrations ≤15,000 nM, which was 50-fold higher than the mean plasma concentration reached during regular therapy (300 nM). Atosiban did not affect human sperm motility in concentrations of ≤3,000 nM, in other words, 10 times the human mean plasma concentration. Conclusion(s) Clinical application of Atosiban in the proposed indication may be safe for embryos because it is compatible with preimplantation rabbit embryo development and human sperm motility.
S Santos - One of the best experts on this subject based on the ideXlab platform.
-
bryophyllum pinnatum enhances the inhibitory effect of Atosiban and nifedipine on human myometrial contractility an in vitro study
BMC Complementary and Alternative Medicine, 2019Co-Authors: Monica Mennet, S Santos, Christian Haslinger, Ursula Von Mandach, Matthias Hamburger, Ana Paula SimoeswustAbstract:Background The herbal medicine Bryophyllum pinnatum has been used as a tocolytic agent in anthroposophic medicine and, recently, in conventional settings alone or as an add-on medication with tocolytic agents such as Atosiban or nifedipine. We wanted to compare the inhibitory effect of Atosiban and nifedipine on human myometrial contractility in vitro in the absence and in the presence of B. pinnatum press juice (BPJ).
-
bryophyllum pinnatum enhances the inhibitory effect of Atosiban and nifedipine on human myometrial contractility an in vitro study
BMC Complementary and Alternative Medicine, 2019Co-Authors: Monica Mennet, S Santos, Christian Haslinger, Matthias Hamburger, U Von Mandach, Ana Paula SimoeswustAbstract:The herbal medicine Bryophyllum pinnatum has been used as a tocolytic agent in anthroposophic medicine and, recently, in conventional settings alone or as an add-on medication with tocolytic agents such as Atosiban or nifedipine. We wanted to compare the inhibitory effect of Atosiban and nifedipine on human myometrial contractility in vitro in the absence and in the presence of B. pinnatum press juice (BPJ). Myometrium biopsies were collected during elective Caesarean sections. Myometrial strips were placed under tension into an organ bath and allowed to contract spontaneously. Test substances alone and at concentrations known to moderately affect contractility in this setup, or in combination, were added to the organ bath, and contractility was recorded throughout the experiments. Changes in the strength (measured as area under the curve (AUC) and amplitude) and frequency of contractions after the addition of all test substances were determined. Cell viability assays were performed with the human myometrium hTERT-C3 and PHM1–41 cell lines. BPJ (2.5 μg/mL), Atosiban (0.27 μg/mL), and nifedipine (3 ng/mL), moderately reduced the strength of spontaneous myometrium contractions. When BPJ was added together with Atosiban or nifedipine, inhibition of contraction strength was significantly higher than with the tocolytics alone (p = 0.03 and p < 0.001, respectively). In the case of AUC, BPJ plus Atosiban promoted a decrease to 48.8 ± 6.3% of initial, whereas BPJ and Atosiban alone lowered it to 70.9 ± 4.7% and to 80.9 ± 4.1% of initial, respectively. Also in the case of AUC, BPJ plus nifedipine promoted a decrease to 39.9 ± 4.6% of initial, at the same time that BPJ and nifedipine alone lowered it to 78.9 ± 3.8% and 71.0 ± 3.4% of initial. Amplitude data supported those AUC data. The inhibitory effects of BPJ plus Atosiban and of BPJ plus nifedipine on contractions strength were concentration-dependent. None of the test substances, alone or in combination, decreased myometrial cell viability. BPJ enhances the inhibitory effect of Atosiban and nifedipine on the strength of myometrial contractions, without affecting myometrium tissue or cell viability. The combination treatment of BPJ with Atosiban or nifedipine has therapeutic potential.
Piotr Pierzynski - One of the best experts on this subject based on the ideXlab platform.
-
the effect of combined tocolysis on in vitro uterine contractility in preterm labour
Advances in Medical Sciences, 2011Co-Authors: Pawel Kuc, Piotr Pierzynski, Piotr Laudanski, Tadeusz LaudanskiAbstract:ABSTRACT Purpose Animal models have confirmed high efficiency of combined tocolytic treatment in preterm labour. In humans, the recommended doses of tocolytic drugs prolong pregnancy in threatened preterm labour. The aim of the study was to evaluate the inhibitory effect of dual combinations of Atosiban, nifedipine and celecoxib on human myometrial strips contractility on the in vitro model of preterm labour. Material/methods Two groups of patients who delivered by cesarean section were involved in the study: 36 patients who delivered preterm between the 24 th and 34 th week of pregnancy and 40 patients who delivered at term. Myometrial samples were obtained from the lower uterine segment during cesarean sections. Contractile activity was recorded with digital software for each drug combination: Atosiban/nifedipine; Atosiban/celecoxib, nifedipine/celecoxib. Tocolytic efficiency of the drug combinations was assessed using IC 50 parameter – a molar drug concentration inhibiting 50% of contractility. Results The Atosiban/nifedipine combination has shown additive tocolytic effect on myometrial strips contractility in preterm and term patients. The other combinations: Atosiban/celecoxib and nifedipine/celecoxib presented only antagonistic effects in both studied groups. Conclusions The effect of the combined therapy on human myometrial contractility presented in the study could be a base for further in vivo clinical trials.
-
effect of Atosiban on rabbit embryo development and human sperm motility
Fertility and Sterility, 2007Co-Authors: Piotr Pierzynski, Allan D Rasmussen, Bartek Gajda, Zdzislaw Smorag, Waldemar KuczynskiAbstract:Objective To investigate embryotoxic potential and effects on human sperm motility of the mixed vasopressin V 1a /oxytocin receptor antagonist Atosiban considered for novel indication of improvement of uterine receptivity in embryo-transfer recipients. Design One-cell rabbit embryo bioassay and human sperm motility bioassay were performed in control media or in media containing Atosiban. Setting Private center of reproductive medicine and academic research institute of reproduction biotechnology. Animal(s) Rabbit females (New Zealand and California, N=15) aged 4.5–6.5 months. Intervention(s) In vitro exposure of one-cell rabbit embryos and human sperm to Atosiban in the range of therapeutic concentrations clinically occurring in human beings. Main Outcome Measure(s) Embryo development and sperm motility. Result(s) Preimplantation development of one-cell rabbit embryos was not affected by Atosiban in the concentrations ≤15,000 nM, which was 50-fold higher than the mean plasma concentration reached during regular therapy (300 nM). Atosiban did not affect human sperm motility in concentrations of ≤3,000 nM, in other words, 10 times the human mean plasma concentration. Conclusion(s) Clinical application of Atosiban in the proposed indication may be safe for embryos because it is compatible with preimplantation rabbit embryo development and human sperm motility.
-
effect of Atosiban on rabbit embryo development and human sperm motility
Fertility and Sterility, 2007Co-Authors: Piotr Pierzynski, Allan D Rasmussen, Bartek Gajda, Zdzislaw Smorag, Waldemar KuczynskiAbstract:Objective To investigate embryotoxic potential and effects on human sperm motility of the mixed vasopressin V 1a /oxytocin receptor antagonist Atosiban considered for novel indication of improvement of uterine receptivity in embryo-transfer recipients. Design One-cell rabbit embryo bioassay and human sperm motility bioassay were performed in control media or in media containing Atosiban. Setting Private center of reproductive medicine and academic research institute of reproduction biotechnology. Animal(s) Rabbit females (New Zealand and California, N=15) aged 4.5–6.5 months. Intervention(s) In vitro exposure of one-cell rabbit embryos and human sperm to Atosiban in the range of therapeutic concentrations clinically occurring in human beings. Main Outcome Measure(s) Embryo development and sperm motility. Result(s) Preimplantation development of one-cell rabbit embryos was not affected by Atosiban in the concentrations ≤15,000 nM, which was 50-fold higher than the mean plasma concentration reached during regular therapy (300 nM). Atosiban did not affect human sperm motility in concentrations of ≤3,000 nM, in other words, 10 times the human mean plasma concentration. Conclusion(s) Clinical application of Atosiban in the proposed indication may be safe for embryos because it is compatible with preimplantation rabbit embryo development and human sperm motility.
-
inhibitory effect of barusiban and Atosiban on oxytocin induced contractions of myometrium from preterm and term pregnant women
Journal of The Society for Gynecologic Investigation, 2004Co-Authors: Piotr Pierzynski, Adam Lemancewicz, Mats Akerlund, Torsten M. Reinheimer, Tadeusz LaudanskiAbstract:BACKGROUND: A synthetic oxytocin analogue, barusiban, was shown to potently inhibit oxytocin-induced activity of myometrium from term pregnant women. The responsiveness to vasopressin was not influenced by the compound. OBJECTIVE: To test the effect of barusiban and a reference compound, Atosiban, on oxytocin-induced activity of myometrium from women at preterm pregnancy in comparison to myometrium from women at term. METHODS: Fifteen preterm (30-36 gestational weeks) and 12 term pregnant women (38-41 weeks) who underwent cesarean delivery donated myometrial tissue for the study. Concentration-response curves following oxytocin, administration to isolated myometrial strips were recorded in control experiments, in the presence of barusiban at concentrations of 2.5, 25, and 250 nM, and of Atosiban at concentrations of 25, 250, and 750 nM. Effective concentration 50% (EC50) and pA(2) values were calculated. RESULTS: Both antagonists in higher concentrations increased the EC50 values to oxytocin. The median pA(2) value for preterm myometrium with barusiban was 9.76 and with Atosiban 7.86. For term myometrium the corresponding pA(2), results were 9.89 and 7.8 1, respectively. None of these pA(2) values differed to any statistically significant degree. CONCLUSION: The selective oxytocin antagonist, barusiban, concentration-dependently inhibits oxytocin-induced myometrial contractions of both preterm and term myometrium at least as potently as Atosiban. It remains to be determined if the selectivity of barusiban for the oxytocin receptor confers an advantage over Atosiban as a tocolytic in preterm labor. Copyright (C) 2004 by the Society for Gynecologic Investigation. (Less)
Ana Paula Simoeswust - One of the best experts on this subject based on the ideXlab platform.
-
bryophyllum pinnatum enhances the inhibitory effect of Atosiban and nifedipine on human myometrial contractility an in vitro study
BMC Complementary and Alternative Medicine, 2019Co-Authors: Monica Mennet, S Santos, Christian Haslinger, Ursula Von Mandach, Matthias Hamburger, Ana Paula SimoeswustAbstract:Background The herbal medicine Bryophyllum pinnatum has been used as a tocolytic agent in anthroposophic medicine and, recently, in conventional settings alone or as an add-on medication with tocolytic agents such as Atosiban or nifedipine. We wanted to compare the inhibitory effect of Atosiban and nifedipine on human myometrial contractility in vitro in the absence and in the presence of B. pinnatum press juice (BPJ).
-
bryophyllum pinnatum enhances the inhibitory effect of Atosiban and nifedipine on human myometrial contractility an in vitro study
BMC Complementary and Alternative Medicine, 2019Co-Authors: Monica Mennet, S Santos, Christian Haslinger, Matthias Hamburger, U Von Mandach, Ana Paula SimoeswustAbstract:The herbal medicine Bryophyllum pinnatum has been used as a tocolytic agent in anthroposophic medicine and, recently, in conventional settings alone or as an add-on medication with tocolytic agents such as Atosiban or nifedipine. We wanted to compare the inhibitory effect of Atosiban and nifedipine on human myometrial contractility in vitro in the absence and in the presence of B. pinnatum press juice (BPJ). Myometrium biopsies were collected during elective Caesarean sections. Myometrial strips were placed under tension into an organ bath and allowed to contract spontaneously. Test substances alone and at concentrations known to moderately affect contractility in this setup, or in combination, were added to the organ bath, and contractility was recorded throughout the experiments. Changes in the strength (measured as area under the curve (AUC) and amplitude) and frequency of contractions after the addition of all test substances were determined. Cell viability assays were performed with the human myometrium hTERT-C3 and PHM1–41 cell lines. BPJ (2.5 μg/mL), Atosiban (0.27 μg/mL), and nifedipine (3 ng/mL), moderately reduced the strength of spontaneous myometrium contractions. When BPJ was added together with Atosiban or nifedipine, inhibition of contraction strength was significantly higher than with the tocolytics alone (p = 0.03 and p < 0.001, respectively). In the case of AUC, BPJ plus Atosiban promoted a decrease to 48.8 ± 6.3% of initial, whereas BPJ and Atosiban alone lowered it to 70.9 ± 4.7% and to 80.9 ± 4.1% of initial, respectively. Also in the case of AUC, BPJ plus nifedipine promoted a decrease to 39.9 ± 4.6% of initial, at the same time that BPJ and nifedipine alone lowered it to 78.9 ± 3.8% and 71.0 ± 3.4% of initial. Amplitude data supported those AUC data. The inhibitory effects of BPJ plus Atosiban and of BPJ plus nifedipine on contractions strength were concentration-dependent. None of the test substances, alone or in combination, decreased myometrial cell viability. BPJ enhances the inhibitory effect of Atosiban and nifedipine on the strength of myometrial contractions, without affecting myometrium tissue or cell viability. The combination treatment of BPJ with Atosiban or nifedipine has therapeutic potential.